Table 1 Patient demographics and baseline characteristics
Characteristic | N = 51 |
|---|---|
Age, n (%) | |
<65 years | 28 (54.9) |
≥65 years | 23 (45.1) |
Median (range), years | 64.0 (31–84) |
Sex, n (%) | |
Male | 34 (66.7) |
Female | 17 (33.3) |
Race, n (%) | |
White | 35 (68.6) |
Asian | 2 (3.9) |
American Indian or Alaskan | 1 (2.0) |
Black or African American | 1 (2.0) |
Other | 12 (23.5) |
ECOG performance status, n (%) | |
0 | 25 (49.0) |
1 | 26 (51.0) |
Site of primary tumor, n (%) | |
Cutaneous | 28 (54.9) |
Ocular | 16 (31.4) |
Mucosal | 2 (3.9) |
Othera | 5 (9.8) |
Time from initial diagnosis to study entry, years | |
Median | 4.3 |
Range | 0.3–33.5 |
Time since first metastatic disease, months | |
Median | 14.8 |
Range | 2.3–168.9 |
PD-L1 expression (≥1% of tumor cells), n (%) | |
Positive | 19 (37.3) |
Negative | 20 (39.2) |
Not evaluable | 12 (23.5) |
Number of prior lines of therapy for metastatic or locally advanced disease, n (%) | |
0 | 1 (2.0) |
1 | 23 (45.1) |
2 | 17 (33.3) |
≥3 | 9 (18.0) |
Missing | 1 (2.0) |
Median (range) | 2 (0–4) |
Prior anticancer therapy in >5% of patients, n (%) | |
Ipilimumab | 26 (51.0) |
Dacarbazine | 11 (21.6) |
Cisplatin | 8 (15.7) |
Interferon | 6 (11.8) |
Fotemustine | 5 (9.8) |
Gemcitabine | 5 (9.8) |
Treosulfan | 5 (9.8) |
Vemurafenib | 5 (9.8) |
Investigational drug | 4 (7.8) |
Paclitaxel | 3 (5.9) |
Sorafenib | 3 (5.9) |